

Contact: Jennifer Cook Williams
Investor Relations
ImmunoCellular Therapeutics, Ltd.
(360) 668-3701
ir@imuc.com

ImmunoCellular Therapeutics Elects Dr. James Bender to Position of Vice President, Clinical Development

LOS ANGELES, CA – September 23, 2008 – ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company, announced today that it has elected James G. Bender, Ph.D., M.P.H., to the position of vice president, clinical development. Dr. Bender joins the company from biopharmaceutical company IDM Pharma and brings more than 20 years of clinical development experience to IMUC, including experience in stem cell research and development. Dr. Bender also has significant experience in guiding product candidates through their regulatory pathways at the U.S. Food and Drug Administration (FDA) as well as extensive internal management expertise, having managed large teams of up to 20 scientists.

"Jim will be a strong addition to our team, as his clinical development expertise, and especially his deep knowledge of stem cells, will be invaluable to us, particularly as we advance our cancer stem cell vaccine through clinical development," said Manish Singh, Ph.D., president and chief executive officer of IMUC. "Jim's vast experience is highly relevant to the activities we are pursuing at IMUC, so we believe that he is an excellent person to lead our clinical development efforts."

Dr. Bender joins IMUC from IDM Pharma, where he was from 2002 through 2008, serving most recently as director of product development where he led the efforts relating to the clinical development of a cancer vaccine, IDM-2101, for lung cancer. Prior to that, he was at Nexell Therapeutics where he held various positions relating to the development of therapeutic stem cell and cancer vaccine products. Prior to that, Dr. Bender spent 10 years with Baxter Healthcare Corporation, eight years with the University of New Mexico School of Medicine and five years with St. Joseph's Hospital in Albuquerque, New Mexico. He has over 75 scientific publications, is an inventor on 11 U.S. patents and holds a Ph.D. degree in immunology from the University of New Mexico and an M.P.H. in laboratory management from the University of Michigan.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based development stage company that is developing immune based therapies for the treatment of brain and other cancers. IMUC's lead product candidate-a dendritic cell-based vaccine for treating brain tumors-is currently being evaluated in a Phase I clinical trial. Additionally, the company is developing a therapeutic vaccine targeting cancer stem cells for multiple cancer indications and will also begin evaluating its newly acquired monoclonal antibody-related technology for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the need to confirm pre-clinical monoclonal antibody data characterizing distinct antigens between cancers; the risk that monoclonal antibody therapeutics based on disparities in CEA sugar patterns may not prove to be safer or more efficacious than other therapeutics; the risks associated with obtaining FDA clearance to initiate the Phase I trial for the stem cell cancer vaccine in a timely manner or at all; the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates; the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages; the risks associated with obtaining and maintaining patent protection for vaccine and antibody product candidates and the lack of patent coverage for the differential immunization platform discovery technology; and the risk of the ability to retain and recruit senior management personnel. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###